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Tumor Suppressing Pathways Minireview
the many alterations in microsatellite loci seen duringRaymond L. White
somatic development of tumors with defects in theirEccles Institute of Human Genetics
DNA repair systems (Ionov et al., 1993). As the microsat-Howard Hughes Medical Institute
ellite alterations usually do not directly affect gene activ-University of Utah
ity, it seems unlikely that these alterations are underSalt Lake City, Utah 84112
positive selection. Yet mutant alleles of microsatellites are
abundantly represented among this subset of tumors.
The search for the tumor suppressor gene on 18q
Identification of the cell regulatory genes that drive car-
exemplifies this challenge. The initial candidate gene
cinogenesis is one of the major goals in cancer research,
identified in the 18q region, DCC, seemed at first to
resulting in new anticancer drug targets and new thera-
meet the appropriate criteria for a tumor suppressor
peutic and diagnostic approaches. Colon cancer is one gene (Fearon et al., 1990). It was a largegene and restric-
of the best-characterized tumor systems from the per- tion fragment alterations were seen in approximately
spectiveof understanding the geneticevents that under-
10% of tumors. However, the sequences responsible
lie the development of malignancy. One reason for the
for these alterations were found to be present in an
detailed knowledge available in this system is the identi- intron rather than an exon, and resulted from variation
fication of an intermediate in the progression pathway, in a microsatellite sequence. At that time, however, it
the adenomatous polyp, accessible for both histological had not been shown that microsatellite regions show a
and molecular analysis. Characterization of the polyp high frequency of background variation in a subset of
intermediate has allowed discrimination between initiat- colon carcinomas, and it appeared that DCC might be
ing events and progression events. Mutations in the the tumor suppressor gene driving the frequent LOH.
APC gene, for example, are found in the earliest polyps, However, very few of the mutations expected to be seen
initiating the developmentof both inherited and sporadic in the coding sequences of the retained allele were re-
colon adenomas (Groden et al., 1991; Joslyn et al., 1991; vealed in a search of a large sample set of colon tumors
Kinzler et al., 1991; Nishisho et al., 1991). The finding (Cho et al., 1994). Other tests were needed to resolve
that the APC protein is capable of modulating levels of the issue.
b-catenin protein, a downstream effector of the Wnt The report of Takaku et al. (1998) in this issue of Cell
signaling pathway (Rubinfeld et al., 1993; Su et al., 1993), now adds substantial support for a major role for another
suggested that this pathway may be the regulatory tar- important signaling system in colon carcinogenesis, the
get of the APC protein. Recent findings of somatic muta- TGFb pathway, in regulating theprogression of the colon
tions in b-catenin that relieve modulation by APCprotein adenoma to carcinoma. Takaku et al. have examined
confirm the etiologic role of this pathway in colon carci- the role of the SMAD4 gene, which maps to the same
nogenesis (Morin et al., 1996, 1997). region of 18q as DCC, in mediating the progression
An important role for another tumor suppressor gene of intestinal adenomas to carcinoma. Normally, TGFb
involved in colon tumor progression is suggested by the provides a growth-inhibiting differentiation signal in epi-
observation of frequent loss of heterozygosity of DNA thelial cells such as breast and colon. Two-receptors,
marker loci on chromosome 18q in colon tumors (Fearon TGFbRI and TGFbRII, govern the interaction between
et al., 1990). Because mutations in tumor suppressor the cell and the TGFb ligand. Primary binding of the
genes are recessive at the cell level, heterozygous cells ligand occurs with the RII receptor, promoting formation
require loss or inactivation of the normal allele in order of a heterodimer with TGFbRIand activationof signaling.
to reveal their tumorigenic phenotype. Often the normal This leads to a complex set of downstream interactions.
allele is lost through a large deletion, sometimes even The best understood of these is mediated by the SMAD
of the entire chromosomeor chromosome arm. Chromo- family of proteins. SMADs 1, 2, and 3 show tissue speci-
somal locations of tumor suppressor genes are, there- ficity and have a transactivation domain. SMAD4, on
fore, frequently determined by loss of heterozygosity the other hand, is ubiquitously expressed but without
(LOH) at DNA marker loci (Cavenee et al., 1983; Li et al., a transactivation domain. However, SMAD4 does form
1997), setting the stage for a positional cloning effort. oligomers with each of SMADs 1, 2, and 3 that promote
A prediction is that the residual tumor suppressor gene, their translocation to the nucleus (Zhang et al., 1997).
whose functional loss is reflected by the LOH, should This pathway was initially implicated in a subset of
carry a mutation. This is important, as there are often colon tumors by observation of mutations in the gene
several or more candidates in the region defined by encoding TGFb receptor type II associated with the mu-
mapping. tator phenotype of HNPCC syndrome (Markowitz et al.,
Because many genes show a low frequency of muta- 1995). These mutations result from insertions or dele-
tions in tumors, however, a finding of only a low fre- tions of one or a few bases and ablate the cell response
quency of mutation in a candidate gene must be re- to TGFb signaling. However, these mutations represent
garded with caution. An additional confounding problem only a small minority of colon tumors.
is that tumors evolve clonally. A change that occurs Important support for a more general role for this
early during tumorigenesis may be carried along during pathway in carcinogenesis came with the finding that
the growth and evolution of the tumor without having mutations in two downstream effector components of
the TGFb signaling pathway, SMAD4 and SMAD2, couldserved an etiologic role. A good example is provided by
Cell
592
be found in colon carcinomas (Eppert et al., 1996; Thia- evidence, both mutational and functional, are needed
to confirm identification of a somatically defined tumorgalingam et al., 1996). Their role was suggested by the
finding of a high frequency of mutation in SMAD4 in suppressor. The finding of a low frequency of mutation
in a candidate should not be taken as adequate proof.pancreatic tumors (Hahn et al., 1996) and the location
of SMAD4 on human chromosome 18q, in the region Furthermore, the finding that each of SMAD4 and
SMAD2 can show mutations in tumors, and that inacti-that shows frequent LOH in colon and other carcinomas
(Fearon et al., 1990). The mouse knockout observations vating mutations of either would be expected to abro-
gate the TGFb signaling pathway, suggests that eachreported by Takaku provide additional strong evidence
that SMAD4 is a suppressor of colon tumor progression. may be capable of inactivating the tumor suppressor
pathway. Which gene actually drives progression in aThe Takaku experiment depends on the fact that in
mice, the APC gene locus and the SMAD4 locus are specific tumor may only depend on which is the first to
be mutated.both located on the same chromosome. Furthermore,
in mice heterozygous for a mutant APC allele (polyposis
Selected Readingmice), virtually all intestinal adenomas will have lost the
entire chromosome that carries the normal APC allele.
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